Patients with non-small cell lung cancer and the AA genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.